Tudor Investment Corp ET AL Takes $921,000 Position in Amneal Pharmaceuticals, Inc. $AMRX

Tudor Investment Corp ET AL acquired a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the third quarter, HoldingsChannel reports. The fund acquired 92,010 shares of the company’s stock, valued at approximately $921,000.

Other large investors have also recently bought and sold shares of the company. BlackBarn Capital Partners LP boosted its stake in Amneal Pharmaceuticals by 19.6% in the second quarter. BlackBarn Capital Partners LP now owns 3,446,570 shares of the company’s stock valued at $27,883,000 after acquiring an additional 564,916 shares during the period. JPMorgan Chase & Co. raised its position in shares of Amneal Pharmaceuticals by 22.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,332,366 shares of the company’s stock worth $10,779,000 after purchasing an additional 240,676 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in shares of Amneal Pharmaceuticals by 1,440.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,135,799 shares of the company’s stock worth $11,790,000 after purchasing an additional 1,062,045 shares during the last quarter. Walleye Capital LLC lifted its holdings in shares of Amneal Pharmaceuticals by 26.9% in the 2nd quarter. Walleye Capital LLC now owns 708,946 shares of the company’s stock worth $5,735,000 after purchasing an additional 150,104 shares during the last quarter. Finally, AustralianSuper Pty Ltd acquired a new position in Amneal Pharmaceuticals during the 3rd quarter valued at approximately $3,238,000. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Price Performance

Shares of AMRX opened at $11.95 on Tuesday. Amneal Pharmaceuticals, Inc. has a one year low of $6.68 and a one year high of $15.42. The company has a 50-day moving average of $13.56 and a two-hundred day moving average of $12.20. The stock has a market cap of $3.76 billion, a price-to-earnings ratio of 51.96 and a beta of 1.34.

Analysts Set New Price Targets

Several research firms have recently issued reports on AMRX. Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st. Barclays assumed coverage on shares of Amneal Pharmaceuticals in a research note on Monday, December 8th. They set an “overweight” rating and a $15.00 target price for the company. Zacks Research raised Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Friday, March 6th. Finally, Truist Financial raised their price objective on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $14.20.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.